The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Reversal of Cisplatin Resistance by Epigallocatechin Gallate Is Mediated by Downregulation of Axl and Tyro 3 Expression in Human Lung Cancer Cells

  • Kim, Kyung-Chan (Department of Internal Medicine, College of Medicine, Catholic University of Daegu) ;
  • Lee, ChuHee (Department of Biochemistry and Molecular Biology, School of Medicine, Yeungnam University)
  • Received : 2013.11.11
  • Accepted : 2013.12.26
  • Published : 2014.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Lung cancer is still the number one cause of death from cancer worldwide. The clinical effect of platinum-based chemotherapy for non-small cell lung cancer is constrained by the resistance to drug. To overcome chemo-resistance, various modified treatment including combination therapy has been used, but overall survival has not been improved yet. In this study, chemo-resistant lung cancer cells, A549/Cis and H460/Cis, were developed by long-term exposure of cells to cisplatin and the proliferative capability of these resistant cells was verified to be reduced. We found cytotoxic effect of epigallocatechin gallate (EGCG), a major catechin derived from green tea, on both the parental lung cancer cells, A549 and H460, and their cisplatin resistant cells, A549/Cis and H460/Cis. ELISA and Western blot analysis revealed that EGCG was able to increase interlukine-6 (IL-6) production per cell, whereas its downstream effector Signal transducers and activators of transcription 3 (STAT3) phosphorylation was not changed by EGCG, indicating that IL-6/STAT3 axis is not the critical signaling to be inhibited by EGCG. We next found that EGCG suppresses the expression of both Axl and Tyro 3 receptor tyrosine kinases at mRNA and protein level, explaining the cytotoxic effect of EGCG on lung cancer cells, especially, regardless of cisplatin resistance. Taken together, these data suggest that EGCG impedes proliferation of lung cancer cells including their chemo-resistant variants through downregulation of Axl and Tyro 3 expression.

Keywords

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29. https://doi.org/10.3322/caac.20138
  2. Ferreira CG, Huisman C, Giaccone G. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol. 2002;41:57-77. https://doi.org/10.1016/S1040-8428(01)00197-4
  3. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548-5557. https://doi.org/10.1038/sj.onc.1203957
  4. Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Göhring W, Ullrich A, Timpl R, Hohenester E. Structural basis for Gas6-Axl signalling. EMBO J. 2006;25:80-87. https://doi.org/10.1038/sj.emboj.7600912
  5. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, Mattsson K, Fisher J, Gies DR, Jones PF, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell. 1995;80:661-670. https://doi.org/10.1016/0092-8674(95)90520-0
  6. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, Chuang SE. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett. 2008; 268:314-324. https://doi.org/10.1016/j.canlet.2008.04.017
  7. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009;69:6871-6878. https://doi.org/10.1158/0008-5472.CAN-08-4490
  8. Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, Kallop D, Ludlam MJ, Pei L. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 2009;28:3442-3455. https://doi.org/10.1038/onc.2009.212
  9. Dunne PD, McArt DG, Blayney JK, Kalimutho M, Greer S, Wang T, Srivastava S, Ong CW, Arthur K, Loughrey M, Redmond K, Longley DB, Salto-Tellez M, Johnston PG, Van Schaeybroeck S. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin Cancer Res. 2013. [Epub ahead of print]
  10. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, Wu CW. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia. 2005;7:1058-1064. https://doi.org/10.1593/neo.05640
  11. Quong RY, Bickford ST, Ing YL, Terman B, Herlyn M, Lassam NJ. Protein kinases in normal and transformed melanocytes. Melanoma Res. 1994;4:313-319. https://doi.org/10.1097/00008390-199410000-00008
  12. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA, Giaccia AJ. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res. 2010;70:7570-7579. https://doi.org/10.1158/0008-5472.CAN-10-1267
  13. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol. 2005; 204:36-44. https://doi.org/10.1002/jcp.20265
  14. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther. 2011;10:1763-1773. https://doi.org/10.1158/1535-7163.MCT-11-0116
  15. Al-Ajmi N, Al-Maghrebi M, Renno WM. (-)-Epigallocatechin- 3-gallate modulates the differential expression of survivin splice variants and protects spermatogenesis during testicular torsion. Korean J Physiol Pharmacol. 2013;17:259-265. https://doi.org/10.4196/kjpp.2013.17.4.259
  16. Yoon SS, Ahn KS, Kim SH, Shim YM, Kim J. In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype. Lung Cancer. 2001;33:221-228. https://doi.org/10.1016/S0169-5002(01)00205-7
  17. Wang J, Wang H, Zhao L, Fan S, Yang Z, Gao F, Chen L, Xiao GG, Molnár J, Wang Q. Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines. Anticancer Res. 2010;30:3593-3598.
  18. Shiau YC, Tsai SC, Wang JJ, Ho YJ, Ho ST, Kao CH. To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer. Cancer Lett. 2001;169:181-188. https://doi.org/10.1016/S0304-3835(01)00519-5
  19. Farabegoli F, Barbi C, Lambertini E, Piva R. (-)-Epigallocatechin- 3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detect Prev. 2007;31:499-504. https://doi.org/10.1016/j.cdp.2007.10.018
  20. Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 2003;63:8118-8121.
  21. Li GX, Chen YK, Hou Z, Xiao H, Jin H, Lu G, Lee MJ, Liu B, Guan F, Yang Z, Yu A, Yang CS. Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis. 2010;31:902-910. https://doi.org/10.1093/carcin/bgq039
  22. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3:651-662. https://doi.org/10.1038/nrm909
  23. Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS, Huang CY. IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2005;289:L446-453. https://doi.org/10.1152/ajplung.00089.2005
  24. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220-241. https://doi.org/10.3322/caac.21149
  25. Wu H, Xin Y, Xiao Y, Zhao J. Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Cancer Biother Radiopharm. 2012;27:204-209. https://doi.org/10.1089/cbr.2011.1103
  26. Mazumder ME, Beale P, Chan C, Yu JQ, Huq F. Epigallocatechin gallate acts synergistically in combination with cisplatin and designed trans-palladiums in ovarian cancer cells. Anticancer Res. 2012;32:4851-4860.
  27. Yang XW, Wang XL, Cao LQ, Jiang XF, Peng HP, Lin SM, Xue P, Chen D. Green tea polyphenol epigallocatechin-3-gallate enhances 5-fluorouracil-induced cell growth inhibition of hepatocellular carcinoma cells. Hepatol Res. 2012;42:494-501. https://doi.org/10.1111/j.1872-034X.2011.00947.x
  28. Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol. 2012; 360:52-58. https://doi.org/10.1016/j.mce.2011.05.033
  29. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R 3rd, Le Beau MM, Earp HS, Liu ET. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991;11:5016-5031.
  30. Neubauer A, O'Bryan JP, Fiebeler A, Schmidt C, Huhn D, Liu ET. Axl, a novel receptor tyrosine kinase isolated from chronic myelogenous leukemia. Semin Hematol. 1993;30(3 Suppl 3):34.
  31. Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M. Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer. 2001; 37:2264-2274. https://doi.org/10.1016/S0959-8049(01)00271-4
  32. Linger RM, Keating AK, Earp HS, Graham DK. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets. 2010;14: 1073-1090. https://doi.org/10.1517/14728222.2010.515980
  33. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, Weimer R, Wu Y, Pei L. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene. 2010;29:5254-5264. https://doi.org/10.1038/onc.2010.268
  34. Postel-Vinay S, Ashworth A. AXL and acquired resistance to EGFR inhibitors. Nat Genet. 2012;44:835-836. https://doi.org/10.1038/ng.2362
  35. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012;44: 852-860. https://doi.org/10.1038/ng.2330

Cited by

  1. Epigallocatechin-3-Gallate Enhances the Therapeutic Effects of Leptomycin B on Human Lung Cancer A549 Cells vol.2015, pp.None, 2015, https://doi.org/10.1155/2015/217304
  2. The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells vol.15, pp.None, 2014, https://doi.org/10.1186/s12906-015-0721-5
  3. The Reversal Effect and Its Mechanisms of Tetramethylpyrazine on Multidrug Resistance in Human Bladder Cancer vol.11, pp.7, 2014, https://doi.org/10.1371/journal.pone.0157759
  4. Location and Effects of an Antitumoral Catechin on the Structural Properties of Phosphatidylethanolamine Membranes vol.21, pp.7, 2016, https://doi.org/10.3390/molecules21070829
  5. Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells vol.15, pp.3, 2014, https://doi.org/10.3892/mmr.2017.6111
  6. Morin inhibited lung cancer cells viability, growth, and migration by suppressing miR-135b and inducing its target CCNG2 vol.39, pp.10, 2017, https://doi.org/10.1177/1010428317712443
  7. Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea vol.5, pp.1, 2014, https://doi.org/10.1016/j.ejbas.2017.12.001
  8. Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review vol.58, pp.6, 2014, https://doi.org/10.1080/10408398.2016.1231168
  9. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine vol.14, pp.None, 2019, https://doi.org/10.1186/s13020-019-0270-9
  10. Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer vol.21, pp.2, 2014, https://doi.org/10.3390/ijms21020401
  11. Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer vol.25, pp.14, 2014, https://doi.org/10.3390/molecules25143146